Drug Profile
Research programme: VAP-1 inhibitors - Mallinckrodt
Alternative Names: RTU-009Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator R-Tech Ueno
- Developer Mallinckrodt plc
- Class Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral infarction; Graft-versus-host disease
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Cerebral-infarction(Combination therapy) in Japan (IV, Injection)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Graft-versus-host-disease(Adjunctive treatment) in Japan (IV, Injection)
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc